Intent to Sole Source Contract to Harvard Pilgrim Health Care Inc..

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

FDA NEGOTIATED CONTRACTS BRANCH

Contract Value

Not provided

Codes & Classification
Solicitation Number

FDA_716A2026

NAICS

-

Classification Code

B537

Additional Details
Set Aside

None

Place of Performance

Silver Spring, Maryland, UNITED STATES

SourceSAM
Documents2
The U.S. Food and Drug Administration (FDA), operating under the Department of Health and Human Services, has issued a Special Notice indicating its intent to award a sole source contract to Harvard Pilgrim Health Care Inc. (HPHCI). This procurement, identified by FDA_716A2026, is focused on securing data retention and analysis services to support the continuation of critical surveillance safety research. The contract is structured to cover a four-year period, commencing on September 29, 2026, and concluding on September 28, 2030. The scope of work encompasses both essential base requirements and optional add-on services, as detailed in the accompanying Statement of Work and Intent Notice attachments. The primary objective of this procurement is to ensure the uninterrupted retention and sophisticated analysis of data necessary for ongoing safety surveillance research. These services are integral to the FDA’s mission of safeguarding public health by enabling robust, evidence-based decision-making regarding the safety of regulated products. The deliverables under this contract will include comprehensive data management, secure retention protocols, and advanced analytical support tailored to the FDA’s surveillance needs. The place of performance for this contract is Silver Spring, Maryland, which serves as a central hub for FDA operations. The procurement is classified under Product Service Code B537, which pertains to specialized research and development services in the health sector. This notice is issued by the FDA Negotiated Contracts Branch, a federal office within the FDA, and is currently active. Interested parties should note that this is a sole source procurement, meaning the FDA has determined that Harvard Pilgrim Health Care Inc. is uniquely qualified to fulfill these requirements, and no competitive solicitation will be issued. As such, this opportunity is not set aside for small businesses or other socioeconomic categories. For further information or to express concerns regarding this sole source determination, interested parties may contact the designated FDA representatives: Howard Yablon ([email protected]) and Ian Weiss ([email protected]). The notice was posted on July 17, 2026, with a response deadline of July 30, 2026. Contractors evaluating this opportunity should consider the specialized nature of the required services, the long-term commitment, and the critical role these activities play in supporting the FDA’s public health mission. The full details, including the Statement of Work, are available via the provided SAM.gov link.